Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 19, 2024

Acalabrutinib With or Without Obinutuzumab vs Zanubrutinib Monotherapy for Treatment-Naïve CLL Without Del(17p)

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL
Blood Adv 2024 Apr 10;[EPub Ahead of Print], AS Kittai, JN Allan, D James, H Bridge, M Miranda, AS Yong, F Fam, J Roos, V Shetty, AP Skarbnik, MS Davids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading